Texas Yale Capital Corp. Buys 4,000 Shares of CorMedix Inc. (NASDAQ:CRMD)

Texas Yale Capital Corp. boosted its position in CorMedix Inc. (NASDAQ:CRMD) by 25.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 20,000 shares of the company’s stock after acquiring an additional 4,000 shares during the quarter. Texas Yale Capital Corp.’s holdings in CorMedix were worth $162,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in CRMD. Advisory Services Network LLC purchased a new position in shares of CorMedix during the 4th quarter valued at about $418,000. Renaissance Technologies LLC bought a new stake in shares of CorMedix in the 4th quarter worth approximately $1,085,000. Invesco Ltd. boosted its stake in shares of CorMedix by 18.1% in the 4th quarter. Invesco Ltd. now owns 24,703 shares of the company’s stock valued at $200,000 after purchasing an additional 3,784 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of CorMedix during the 4th quarter valued at $205,000. Finally, Wells Fargo & Company MN raised its position in CorMedix by 57.9% in the 4th quarter. Wells Fargo & Company MN now owns 30,421 shares of the company’s stock worth $246,000 after purchasing an additional 11,155 shares during the period. Hedge funds and other institutional investors own 34.18% of the company’s stock.

CorMedix Trading Down 2.3 %

Shares of NASDAQ CRMD opened at $6.84 on Friday. The firm has a fifty day simple moving average of $9.28 and a two-hundred day simple moving average of $9.84. CorMedix Inc. has a 12 month low of $3.61 and a 12 month high of $13.85. The firm has a market capitalization of $445.84 million, a PE ratio of -8.44 and a beta of 1.57.

CorMedix (NASDAQ:CRMD) last posted its quarterly earnings data on Tuesday, March 25th. The company reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.17 by $0.05. The firm had revenue of $30.00 million for the quarter, compared to the consensus estimate of $27.46 million. The firm’s revenue for the quarter was up 29900.0% on a year-over-year basis. On average, sell-side analysts predict that CorMedix Inc. will post -0.32 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on CRMD shares. StockNews.com raised CorMedix from a “sell” rating to a “hold” rating in a research note on Tuesday, April 1st. Leerink Partnrs upgraded CorMedix to a “strong-buy” rating in a research report on Friday, March 7th. D. Boral Capital reiterated a “buy” rating and issued a $15.00 price objective on shares of CorMedix in a research report on Tuesday. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $12.00 target price on shares of CorMedix in a research note on Wednesday, March 26th. Finally, Needham & Company LLC reissued a “buy” rating and set a $12.00 price target on shares of CorMedix in a research report on Wednesday. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, CorMedix currently has an average rating of “Buy” and a consensus target price of $14.50.

CorMedix Company Profile

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.